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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not “Is 
administration of marijuana effective in reducing pain”  
Study Design: Systematic review of 2 randomized, double-blind placebo controlled trials 
(RCTs) and 1 cohort study published after July 2016.  
Data Sources:  Both RCTs and the cohort study were found through the PubMed database  
Outcome(s) measured: All 3 studies utilized the 11-point numerical rating scale to measure pain 
intensity. 
Results: Wilsey et. al showed a notable improvement in pain intensity when participants inhaled 
both 2.9% delta 9-THC and 6.7% delta 9-THC concentrations when compared to visually 
matched placebo with no significant distinction between the lower and higher concentrations of 
delta 9-THC at the end of 7 hours. Although Schimrigk et. al did show pain reduction with 
administration of both dronabinol (PO form of THC) and placebo after 16 weeks, the results 
between the two were not significant when compared to each other. Lastly, the cohort study 
performed by Vigil et al. did reflect a significant change in pain intensity reduction after self-
administrated use of marijuana after 12 months.  
Conclusion: This EBM review demonstrated that marijuana is an safe, effective treatment option 
for chronic pain patients looking to reduce their pain intensity.  Although marijuana should not 
replace current conventional medical therapies, it may serve as an alternative for patients willing 
to try other options for pain relief.  
Introduction     
 Pain is a component of many physical and mental health conditions, which can limit daily 
life and work activities for certain individuals, as well as contribute to high healthcare costs. Pain 
can be classified as acute or chronic, with chronic pain being defined as lasting more than 12 
weeks. 1 There are many etiologies of pain, which can include but are not limited to: injuries/
post-operation incision pain, being related to a condition (ex. herniated discs, arthritis, migraines, 
multiple sclerosis, cancer, nerve damage), or even those without an apparent cause 
(fibromyalgia).  
 Pain is one of the most common reasons for Americans to access the healthcare system 
presently. Among pain sufferers, 63% have visited their PCP, 40% have visited specialists, and 
25% have visited a pain management physician or chiropractor. 2  There are an estimated 100 
million U.S. adults living with chronic pain, making this affect more people than diabetes, heart 
disease, and cancer combined. Unfortunately, this translates to contributing to an estimated 
$560-635 billion each year in direct medical costs, lost productivity, and disability resources. 2 
Without proper pain relief, people may be reluctant to attend work, leading to difficulties with 
maintaining employment and thus insurance coverage. This can result in depression and a host of 
other health issues. Because chronic pain is the leading cause of long-term disability, it is 
therefore extremely important for healthcare practitioners to understand the different approaches 
in pain management for the diversity of conditions they may treat, while maintaining quality of 
life for each individual patient. 
 While extensive research on pain has been exceptionally beneficial, not all is fully 
understood about the multiple microbiological mechanisms that can be involved in pain. We do 
understand the basic pathophysiology behind many types of pain as well as the 
pharmacodynamics of many drugs we use to treat pain, such as over-the-counter analgesics, 
opioid medications, and even medical marijuana. However, it becomes increasingly difficult 
because pain is largely a subjective experience and there can be psychosocial contributors that 
can modify pain levels such as stress, anxiety, and weather. 3 While there are indeed many 
different tools healthcare practitioners can use to assess the cause of pain such as radiological 
imaging, blood tests, electromyography, etc., the results may not correlate to what a patient may 
actually be personally expressing.  
 Depending on the specific etiology, there are a number of conventional treatment options 
to treat pain. These can be broken down into the categories of: medications, therapy, procedures, 
and self-care. Medications include acetaminophen, NSAIDs, COX-2 inhibitors, opioids, 
antidepressants, anti-epileptics, and others. Therapy may include physical therapy, massage, 
cognitive behavioral therapy, acupuncture, and others. Procedures include nerve blocks and 
surgery. Lastly, self-care in the form of relaxation techniques, diet, and stretching techniques can 
also be utilized. Effective management for chronic pain may require using many different 
options and including the coordinated efforts of many healthcare professionals to obtain the best 
results.  
 Marijuana is being researched as an alternative for chronic pain management. With our 
current opioid epidemic leading to increasing overdose death rates and new CDC guidelines of 
maintaining less than or equal to 90 morphine milligram equivalents (MME) a day, there needs 
to be safer and similarly effective options for patients suffering from chronic pain. When 
compared to opioid prescriptions, marijuana options generally have less severe side effects. Even 
despite today’s marijuana products being more potent than in the past, there have been no deaths 
from overdoses with marijuana alone according to the DEA. 4 In addition, marijuana may help 
promote sleep, increase appetite, and relieve nausea - relieving some additional symptoms 
patients with chronic pain may concurrently suffer from.   
Objective 
 The objective of this selective EBM review is to determine whether or not: “Is 
administration of marijuana effective in reducing pain?”  
Methods 
 Among the 3 studies used in this EBM review, 2 were randomized double-blind, placebo 
controlled trials and 1 was a cohort study. All three studies included chronic pain patients who 
were adults over the age of 18. The interventions for the two RCTs included marijuana 
administration compared to visually matched placebo, and they looked at pain severity changes 
before and after. Wilsey et al. used 2.9% and 6.7% delta 9-THC vaporized marijuana, 5 while 
Schimrigk used a patient tolerable dose of dronabinol (PO form of THC) following a 4 week 
titration period. 6 The RCT performed by Wilsey et al. included a crossover design, so all patients 
were exposed to both dosages of vaporized marijuana as well as placebo on separate days 3 days 
apart to permit the metabolic breakdown of delta 9-THC metabolites. 5 The cohort study by Vigil 
et al. looked at chronic pain patients, who had filled at least 2 opioid prescriptions during the 3 
months prior to enrollment into the New Mexico Medical Cannabis Program (MCP) or not 
enrolling. The researchers then gathered prescription records during a 21 month period (which 
includes the 3 months) regarding differences between opioid prescription refills between MCP 
enrolled patients and those who did not enroll. They also sent surveys to MCP enrolled patients 
after 12 months to see if self-managed administration of marijuana improved pain severity. 7 
Outcomes for all three studies measured were changes in pain level after administration of 
marijuana. 
 Data  sources were searched using the key words: “marijuana” and “chronic pain” in 
PubMed-NCBI. The studies were chosen if they addressed the research question and whether the 
outcomes addressed Patient-Oriented Evidence that Matters (POEMs). All articles were 
published in English in peer-reviewed journals and dated after July 2016 with adult chronic pain 
patients over the age of 18. Patients with significant mental health histories, substance abuse, and 
co-morbidities that could lead to a deleterious effect on well-being (ie. severe cardiac disease) 
were excluded. The mean change from baseline, p-value, CI, and NNT were statistics used to 
determine significance.    
Table 1 - Demographics & Characteristics of included studies  
Study Type # Pts Age (yrs) Inclusion criteria Exclusion criteria W
/D
Interventions
Wilsey  
(2016) 3
Randomized, 
double-blind, 
placebo 
controlled, 
crossover 
design study
42 age >18 and 
< or = to 70 
years
- age >18 and < or = to 
70 years  
- pain intensity > or = to 
4 on a 11-point pain 
intensity numerical 
rating scale 
- > or = to 12 on Leeds 
Assessment of 
Neuropathic Symptoms 
and Signs to 
substantiate 
neuropathic pain 
- those with 
significant 
mental health 
Hx 
- co-morbidities 
leading to a 
deleterious 
effect on well-
being (x. severe 
heart dz)   
- substance abuse
0 Inhalation of 
vaporized 2.9% and 
6.7% delta 9-THC  
Schimri
gk 
(2017) 4
Randomized, 
double- blind, 
placebo-
controlled 
design study 
240 age >18 and 
< or = to 70 
years
- age >18 and < or = to 
70 years MS pts 
- pain intensity > or = to 
4 on a 11-point pain 
intensity numerical 
rating scale 
- any peripheral 
pain syndromes  
- preexisting 
psychotic 
disorders  
- severe cardiac 
dz 
- substance abuse 
31 Administration of 
dronabinol (THC) 
patient specific 
tolerable dose 
following a 4 week 
titration period 
Vigil 
(2017) 5
Cohort study 37 Did not 
specifically 
mention;  
experimenta
l group 
mean age = 
54 y/o 
control 
group mean 
age = 60 y/o
- pts diagnosed with 
“severe chronic pain” 
by 2 independent 
physicians 
- pts must have filled at 
least 2 opioid Rx 
during the 3 mo prior 
(with max daily 
dosages of less than 
200mg IV morphine 
equivalence) 
- pts who did not 
fill at least 2 
opioid 
prescriptions 
during the 3 mo 
prior 
- inflammatory 
diseases 
3 Self-managed 
administration of 
cannabis products  
Outcomes Measured 
 Wilsey et al. used the 11-point numerical rating scale (0= no pain to 10 = strongest pain 
imaginable) to measure pain intensity before and after administration of marijuana. Marijuana or 
placebo were administered at hours 1 and 4. Each patient was assessed at baseline (hour 0) 
before intervention and at 1 hour intervals up to hour 7. 5 The scores were compared between the 
groups receiving 2.9% delta-9 THC, 6.7% delta-9 THC, and placebo to see if there was a 
difference in improvement in pain intensity.  
 Schimrigk et al. also used the 11-point numerical rating scale to measure pain intensity 
before and after administration of dronabinol. Dronabinol or placebo were administered at week 
0, and mean change of pain intensity from baseline to mean weekly pain scores were measured 
up to week 16. 6 The 2 groups were compared to see if there was a significant change in pain 
intensity during these 16 weeks. 
 Vigil et al. looked at prescription records for opioid prescribed patients enrolled in the 
New Mexico Medical Cannabis Program (MCP) and compared them to those not in the program 
to see if there was a reduction in opioid medication refills. In addition, they assessed if self-
managed administration of marijuana improved pain severity for patients after 1 year of being 
enrolled into the MCP with the 11-point numerical rating scale to measure pain intensity. 
Unfortunately, this same information was not obtained from the comparison group.   
Results 
  This review used 2 randomized, double-blind placebo controlled trials and 1 cohort study 
to look at the efficacy of marijuana and its relation in improving pain intensity for patients with 
chronic pain. The inclusion and exclusion criteria for all of these studies can be referenced from 
Table 1.  
 Wilsey et al. utilized 42 participants randomized into 1 of 3 treatment groups: 2.9% delta 
9-THC, 6.7% delta 9-THC, and visually matched placebo. Since this study was a crossover 
design study, all patients received all 3 treatment options on different study days. At baseline, 
there was no reported significant mean pain intensities differences between the 3 groups (p > 
0.6). 5 After 1 hour of administration of the first treatment dose, it was found that pain intensity 
was significantly lower for the 2 experimental groups compared to control (p <0.05) with 6.7% 
delta 9-THC retaining significance for the next 2 hours (p <0.01). 5 After administration of the 
second treatment dose, this also showed that pain intensity was lower for both experimental 
groups compared to control (p<0.05), although the effect on pain showed no significant 
distinction between 2.9% delta 9-THC and 6.7% delta 9-THC (p>0.11) at hour 7. 5 Using a 
reduction of pain intensity of  ≥30% as clinically important, it was determined that 18 placebo 
patients, 26 lower dose THC patients, and 35 higher dose THC patients met this criteria. 5 The 
NNT to obtain 30% pain reduction was 4 for the lower dose and 3 for the higher dose when 
compared to placebo. 5 These results are summarized in Table 2 below, which also include the 
95% confidence intervals.  No serious adverse events were reported in this study. 
Table 2. Reduction of pain intensity by >30% [defined as clinically important] 
Intervention Placebo Low High
# patients 18 26 35
% patients 45% 70% 88%
95% CI 31-60% 54-83% 74-95%
NNT N/A 4 3
 Schimrigk et al. had a total of 240 participants randomized into 124 dronabinol and 116 
placebo treatment patients. There was no significant differences at baseline for pain between the 
2 groups, with pain intensity values being at 6.4 ± 1.49 (dronabinol) and 6.74 ± 1.41 (placebo). 6 
Although both experimental and control groups showed a clinically relevant pain reduction after 
16 weeks, the mean change of pain intensity from baseline to mean of weeks 1-16 compared 
between dronabinol (1.92 ± 2.01; 30%) and placebo (1.81 ± 1.94; 27%) was not statistically 
significant (p=0.676). 6 Serious adverse events were rare but reported in this study in 3 patients, 
which comprised of dysphoria, constipation, and exacerbation of preexisting pain. 6 
 Vigil et al. had a total of 66 participants divided into 37 patients who enrolled in the MCP 
compared to 29 non-enrolled patients. By the end of the 21 month observation period, it was 
found that 83.8% of MCP patients were more likely to reduce daily opioid dosages compared to 
44.8% non-enrolled patients (p<0.001), and 40.5% of MCP patients ceased filling opioid 
prescriptions altogether compared to 3.4% of non-enrolled patients (p = 0.001). The researchers 
also assessed pain reduction directly using the 11-point numerical rating scale to measure pain 
intensity. They found that 33 of the 34 respondents had a statistically significant change in pain 
intensity at 12 month post-enrollment (mean change = -3.4, p<0.001), shown in table 3. No 
serious adverse events were reported in this study. 
Table 3. Survey responses at 12 months post-MCP enrollment 
Variable Mean ± SD Min Max P-value
Pain prior to MCP 
(0-10)
8.6 ±1.4 4 10 <0.001
Pain after MCP 
(0-10)
5.3 ±1.7 2 10 <0.001
 Discussion  
 The 3 studies that were discussed in this EBM review show that marijuana can impart 
relief on pain intensity for patients with chronic pain. Research continues to prove hopeful for 
the advancement of marijuana to treat pain in addition to many other different medical 
conditions. Currently, there are other clinical trials showing benefit in the treatment of seizures, 
immunological diseases, inflammatory conditions, mental health/substance abuse disorders, and 
even cancer. 11    
 There are several limitations noted in these studies as well as with marijuana in general. 
Both Wilsey et al. and Vigil et al. had sample sizes of less than 50 participants, leading to a 
question of validity to the general population. Wilsey et al. did not address long-term pain 
intensity changes as the studies performed were limited to separate single days. Furthermore, 
Vigil et al. did not obtain information regarding pain intensity changes from the comparison 
group, had 3 non-respondents from the experimental group regarding pain intensity changes, did 
not verify opioid and cannabis usage via drug screen, could not randomize participants, and 
could not monitor the type or amount of marijuana usage in their study. Even though marijuana 
dispensaries are mandated to report laboratory information regarding their marijuana products, 
there are just so many different types of options available (topicals, vaporizer, dried flower, 
edibles, drinks, tablets, sublingual etc.) with different potencies, psychoactive effects, and 
medical benefits, so it may be difficult for patients to find the products that work for them. For 
example, ingested products take longer to be absorbed in the body compared to inhaled products, 
Change in pain 
(post-prior)
-3.4 ±2.1 -7 3 <0.001
but they tend to exert their effects longer. With regards to long-term detrimental effects, it is 
known that marijuana may cause mental health disorders, including psychosis. 9 There is also 
supporting evidence regarding long-term use being associated with respiratory issues, such as 
chronic bronchitis and lung cancer as well as risks associated with cardiovascular disease 
patients, such as increases in cardiac workload, increased catecholamine levels, and impaired 
blood oxygen carrying capacity. 10 There is also the limitation of cost for patients, as marijuana 
itself is not a FDA approved drug at the time of this writing, so insurance companies are reluctant 
to offer coverage. 8 This currently results in patients needing to pay out of pocket for this option 
if they wish to pursue it. 
Conclusion 
 This EBM review has demonstrated that marijuana is an safe, effective treatment option 
for chronic pain patients looking to reduce pain intensity. The evidence gathered here from after 
July 2016 complements previous research performed addressing marijuana’s ability to alleviate 
pain. Wilsey et al. found that inhaled marijuana was able to provide significant benefit in pain 
relief for at least 6 hours, when compared to placebo with 2 administered dosages. 5 Despite the 
fact that Schimrigk et al. was unable to show a statistically significant difference between 
dronabinol and placebo, they were able to provide results revealing that dronabinol is a safe 
long-term treatment option for patients with chronic pain. 6 Vigil et al. provided evidence that 
when given the option to use marijuana to self-manage pain over the course of a year, patients 
had improvements in pain intensity, which actually decreased their need to fill their routine 
opioid prescriptions. 7  
 Future areas of research may prove beneficial to explore the different delivery methods 
mentioned above as well as include synthetically synthesized marijuana products in research to 
compare different efficacies. To that note, it would likewise be important to evaluate potency, 
dosing, and the effects of the individual components comprised in the makeup of marijuana. 
Dependence and tolerance are other issues to evaluate as it is with any drug. Another important 
consideration is the impact on marijuana on daily functioning and mood, which were not 
explicitly addressed in the 3 presented studies. Lastly, it is extremely important to increase 
validity and reliability by increasing sample size and having longer treatment times. Although 
marijuana should not replace current conventional medical therapies, it may serve as an 
alternative for patients willing to try other options for pain relief. Hopefully, ongoing research in 
the next couple years continues to shed more light on the benefits and disadvantages in using 
marijuana to manage pain, leading to wider acceptance by both patients and healthcare 
practitioners alike.   
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